Vaccines

Global Influenza Vaccines Markets 2019-2020 & Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 5, 2020
Health, Infectious diseases, Vaccination, Medical specialties, RTT, Vaccines, Health, Influenza vaccine, Vaccine, Influenza vaccines, Influenza, Live attenuated influenza vaccine, Influenza A virus subtype H3N2

The "Global Influenza Vaccines Market 2019-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Influenza Vaccines Market 2019-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global influenza vaccines market is predicted to grow at a CAGR of 6.20% during the forecasting period 2019-2028.
  • The rapid advancements in technology in the field of vaccine development are driving the growth of the global influenza vaccines market.
  • This factor, along with the rising healthcare expenditure in these countries, is likely to boost the growth of the influenza vaccines market in the region.

RDIF announces delivery of the first batch of Sputnik V vaccine to Venezuela for clinical trials

Retrieved on: 
Friday, October 2, 2020
Health, Vaccines, Vaccination, Medicine, COVID-19 pandemic in Russia, Gam-COVID-Vac, Science and technology in Russia, Clinical research, Russian Direct Investment Fund, Clinical trial

MOSCOW, Oct. 2, 2020 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, announces the delivery of the first batch of the Russian vaccine against coronavirus, Sputnik V, to the Bolivarian Republic of Venezuela.

Key Points: 
  • MOSCOW, Oct. 2, 2020 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, announces the delivery of the first batch of the Russian vaccine against coronavirus, Sputnik V, to the Bolivarian Republic of Venezuela.
  • Vaccination of volunteers in Venezuela will begin in coming days as part of double-blind, randomized, placebo-controlled clinical trials of the Sputnik V vaccine.
  • Venezuela has become the first country in Latin America to start clinical trials of the Sputnik V vaccine after its registration in Russia with 2000 people taking part in the trial.
  • Post-registration clinical trials of the Sputnik V vaccine involving 40,000 volunteers are currently ongoing.

Moderna, Pfizer & BioNTech, and AstraZeneca and the University of Oxford's COVID-19 Vaccine Trials are Entering the Final Stage of Development

Retrieved on: 
Friday, October 2, 2020
Articles, Health, Medical research, Vaccines, Moderna, BioNTech, Pfizer, AstraZeneca, Vaccine, Johnson & Johnson, COVID-19 vaccine, Influenza research

The company will trial the vaccine with 60,000 volunteers from around the world including participants from the US, South Africa, Brazil, Argentina, Columbia, and Chile.

Key Points: 
  • The company will trial the vaccine with 60,000 volunteers from around the world including participants from the US, South Africa, Brazil, Argentina, Columbia, and Chile.
  • Johnson & Johnson's vaccine joins candidates developed by Moderna, Pfizer and BioNTech, and AstraZeneca and the University of Oxford in beginning the final stage of development.
  • The company has committed to manufacturing a billion doses of the vaccine on a not for profit basis if proven effective.
  • In contrast to other vaccine candidates that require at least two doses, J&J's candidate requires just one dose.

Health Canada begins first authorization review of a COVID-19 vaccine submission

Retrieved on: 
Friday, October 2, 2020
Medicine, Articles, Vaccines, Health, Medical research, COVID-19 vaccine, AstraZeneca, Vaccine, Gam-COVID-Vac, COVID-19 drug development

OTTAWA, ON, Oct. 2, 2020 /CNW/ - Yesterday, Health Canada received its first submission for authorization of a COVID-19 vaccine developed by AstraZeneca in partnership with the University of Oxford.

Key Points: 
  • OTTAWA, ON, Oct. 2, 2020 /CNW/ - Yesterday, Health Canada received its first submission for authorization of a COVID-19 vaccine developed by AstraZeneca in partnership with the University of Oxford.
  • Health Canada will be doing a rolling review of AstraZeneca's vaccine data to make sure it meets the Department's rigorous safety and efficacy requirements.
  • Following the authorization of any vaccine submission, Health Canada will publish the evidence it reviewed in making its decision for transparency.
  • Earlier this month, the Prime Minister announced that Canada has signed an agreement with AstraZeneca to buy 20 million doses of its COVID-19 vaccine, should that vaccine successfully complete clinical trials and be authorized by Health Canada.

Meridian Clinical Research Wins Vaccine Industry Excellence (ViE) Awards for Best Clinical Trial Site and Best Clinical Trial Network in 2020

Retrieved on: 
Thursday, October 1, 2020
Clinical research, Health research, Articles, Health, Medical research, Vaccines

OMAHA, Neb., Oct. 1, 2020 /PRNewswire-PRWeb/ -- Meridian Clinical Research , a leading investigative research network, won the 2020 Vaccine Industry Excellence (ViE) award for Best Clinical Trial Site.

Key Points: 
  • OMAHA, Neb., Oct. 1, 2020 /PRNewswire-PRWeb/ -- Meridian Clinical Research , a leading investigative research network, won the 2020 Vaccine Industry Excellence (ViE) award for Best Clinical Trial Site.
  • Meridian is also the largest member of Platinum Research Network , which won the ViE award for Best Clinical Trial Network.
  • "It's incredible to earn these awards when vaccine trials are the industry's priority and so visible in the public spotlight," said Nicole Osborn , Meridian founder and CEO.
  • Meridian Clinical Research partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, and diagnostics that could improve human health and wellbeing.

Informa Pharma Intelligence Launches New Pulse Report: Clinical Trials & the COVID-19 Vaccine

Retrieved on: 
Thursday, October 1, 2020
Health, Medicine, Articles, Medical research, Vaccines, Clinical research, Drug discovery, Pharmaceutical industry, COVID-19 vaccine, Vaccine, Clinical trial, Gam-COVID-Vac

LONDON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence , the global business intelligence provider for the biopharma industry, today released its Pulse Report: Clinical Trials & the COVID-19 Vaccine study which uncovered American sentiment and confidence around COVID-19 vaccine clinical trials.

Key Points: 
  • LONDON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence , the global business intelligence provider for the biopharma industry, today released its Pulse Report: Clinical Trials & the COVID-19 Vaccine study which uncovered American sentiment and confidence around COVID-19 vaccine clinical trials.
  • According to the data, more than 1 in 3 (35%) Americans dont trust how quickly the COVID-19 vaccine clinical trials are moving, and more than 1 in 5 (23%) dont think pharmaceutical companies have consumers best interests at mind during COVID-19 vaccine clinical trials.
  • Right now, 1 in 5 Americans agree that both pharmaceutical companies and the government are NOT communicating enough about COVID-19 vaccine clinical trials (20% and 21% respectively).
  • Many Americans say theyre more likely to take the COVID-19 vaccine if they:
    Had more information on clinical trials: more than 1 in 4 (28%)
    Knew the demographic breakdowns of clinical trials were diverse: almost 1 in 6 (15%)
    Could directly ask questions about clinical trials to vaccine developers: more than 1 in 10 (12%)
    Knew someone who had participated in a clinical trial: more than 1 in 10 (11%)
    Theres a clear demand for unbiased information from the American public when it comes to COVID-19 vaccine clinical trials, said Duncan Emerton, PhD, Director, Custom Intelligence & Analytics, Pharma Intelligence.

US Health Officials Urge Influenza and Pneumococcal Vaccination Amid COVID-19 Pandemic

Retrieved on: 
Thursday, October 1, 2020
Articles, Health, Global health, Influenza vaccine, RTT, Vaccines, Pandemic, Influenza A virus subtype H1N1, Swine flu pandemic in the United Kingdom, Flu season

This number is concerning to public health officials, who are bracing for the potential impact from a dual outbreak of flu and COVID-19 this winter.

Key Points: 
  • This number is concerning to public health officials, who are bracing for the potential impact from a dual outbreak of flu and COVID-19 this winter.
  • In fact, 28 percent reported that the COVID-19 pandemic makes them more likely to get vaccinated against flu this year.
  • "In the midst of a pandemic, people should be more motivated than ever before to get a flu vaccine.
  • These individuals must take every possible precaution, including a discussion with their healthcare professionals about vaccination against flu and pneumococcal disease."

VGXI Wins Best Contract Manufacturing Organization for the 2020 Vaccine Industry Excellence Awards

Retrieved on: 
Thursday, October 1, 2020
Medical specialties, Medicine, Health, Vaccination, Vaccine, Virology, CGMP, Medical research, Vaccines, Draft:GeneOne Life Science, Specialty drugs, COVID-19 vaccine

THE WOODLANDS, Texas, Oct. 1, 2020 /PRNewswire-PRWeb/ -- VGXI, Inc., a contract development and manufacturing organization specialized in production of pre-clinical through cGMP grade DNA-based biopharmaceuticals, announced it has been recognized as the winner for Best Contract Manufacturing Organization on September 30, 2020 at the Vaccine Industry Excellence (ViE) Awards.

Key Points: 
  • THE WOODLANDS, Texas, Oct. 1, 2020 /PRNewswire-PRWeb/ -- VGXI, Inc., a contract development and manufacturing organization specialized in production of pre-clinical through cGMP grade DNA-based biopharmaceuticals, announced it has been recognized as the winner for Best Contract Manufacturing Organization on September 30, 2020 at the Vaccine Industry Excellence (ViE) Awards.
  • The ViE Awards are part of the annual World Vaccine Congress in Washington D.C., which was held virtually in 2020 due to the coronavirus pandemic.
  • The awards are designed to highlight the efforts, positive contributions, and accomplishments of companies and individuals across the vaccine industry.
  • VGXI, Inc., GeneOne's wholly-owned manufacturing subsidiary located in Texas, is the largest pure-play cGMP DNA plasmid manufacturing facility in the world.

Scott+Scott Attorneys at Law LLP Reminds Investors of Pending Securities Class Actions Against Vaxart, Inc. (VXRT) and October 23, 2020 Lead Plaintiff Deadline

Retrieved on: 
Thursday, October 1, 2020
Medical research, Articles, Health, Medicine, Vaccines, Vaccination, Vaccine, Virology, Vaxart, COVID-19 vaccine

Vaxart is a small, clinical-stage biotechnology company primarily focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform.

Key Points: 
  • Vaxart is a small, clinical-stage biotechnology company primarily focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform.
  • In late June 2020, Vaxart made a couple of announcements regarding its Covid-19 vaccine and the stock price increased dramatically.
  • Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States.
  • The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

Enesi Pharma's ImplaVax® Solid-Dose and Needle-Free Vaccination Platform Wins Best New Vaccine Technology/Platform Award at the World Vaccine Congress

Retrieved on: 
Thursday, October 1, 2020
Medical specialties, Medicine, Vaccination, Virology, Health, Vaccines, Medical research, Vaccine, Herpes simplex research

The Vaccine Industry Excellence (ViE) Awards honour and recognise the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry and are a highlight of the World Vaccine Congress.

Key Points: 
  • The Vaccine Industry Excellence (ViE) Awards honour and recognise the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry and are a highlight of the World Vaccine Congress.
  • "We are delighted to win the Best New Vaccine Technology/Platform category at such a prestigious global vaccine event.
  • Enesi Pharma is developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax technologies.
  • Our ImplaVax-enabled vaccination products leverage our innovative unit solid-dose formulation and needle-free delivery technologies and are applicable across all vaccine formats.